Personalised Medicine: A Critique on the Future of Health Care

Journal of Bioethical Inquiry

Volumn 10, Issue 2, 2013, Pages 197-203

  Savard, Jacqueline ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Epistemology; Ethics; Health care; Neoliberalism; Ontology; Personalised medicine

Indexed keywords

ARTICLE; ETHICS; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH STATUS; HUMAN; PERSONALIZED MEDICINE; SOCIAL JUSTICE;

DELIVERY OF HEALTH CARE; HEALTH STATUS; HEALTHCARE DISPARITIES; HUMANS; INDIVIDUALIZED MEDICINE; SOCIAL JUSTICE;

EID: 84879178575     PISSN: 11767529     EISSN: 18724353     Source Type: Journal    
DOI: 10.1007/s11673-013-9429-8     Document Type: Article

References (57)

1. Aronowitz, R. A. 2004. When do symptoms become a disease? In Health, disease, and illness: Concepts in medicine, ed. A. L. Caplan, J. J. McCartney, and D. A. Sisti, 65-76. Washington: Georgetown University Press.
2. Baselga, J., L. Norton, J. Albanell, Y. M. Kim, and J. Mendelsohn. 1998. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Research 58(13): 2825-2831.
3. Bentley, D. R. 2004. Genomes for medicine. Nature 429(6990): 440-445.
4. Boorse, C. 1975. On the distinction between disease and illness. Philosophy and Public Affairs 5(1): 49-68.
5. Boorse, C. 1977. Health as a theoretical concept. Philosophy of Science 44(4): 542-573.
6. Burke, W., and B. M. Psaty. 2007. Personalized medicine in the era of genomics. Journal of the American Medical Association 298(14): 1682-1684.
7. Burke, W., H. Burton, A. E. Hall, et al. 2010. Extending the reach of public health genomics: What should be the agenda for public health in an era of genome-based and "personalized" medicine? Genetics in Medicine 12(12): 785-791.
8. Canguilhem, G. 1989. The normal and the pathological. New York: Zone Books. Originally published as Le normal et le pathologique (Paris: Les Presses Universitaires de France, 1966).
9. Canguilhem, G. 2004. The normal and the pathological-introduction to the problem. In Health, disease, and illness: Concepts in medicine, ed. A. L. Caplan, J. J. McCartney, and D. A. Sisti, 40-42. Washington: Georgetown University Press.
10. Caremark, Inc. 1998. Biotechnology breakthrough in breast cancer wins FDA approval. New Drug Review: Caremark New Drug Quick-Facts 1(11): 1.
11. Conti, R., D. L. Veenstra, K. Armstrong, L. J. Lesko, and S. D. Grosse. 2010. Personalized medicine and genomics: Challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Medical Decision Making 30(3): 328-340.
12. Evans, J., and M. J. Khoury. 2007. Evidence-based medicine meets genomic medicine. Genetics in Medicine 9(12): 799-800.
13. Fairclough, N. 1993. Critical discourse analysis and the marketization of public discourse: The universities. Discourse and Society 4(2): 133-168.
14. Foucault, M. 1995. Discipline and punish: The birth of the prison, 2nd edition. Trans. A. Sheridan. New York: Random House. Originally published as Surveiller et punir: Naissance de la prison (Paris: Éditions Gallimard, 1975).
15. Frank, A. W. 2000. All the things which do not fit: Baudrillard and medical consumerism. Families, Systems & Health 18(2): 205-216.
16. Frank, A. W. 2002. What's wrong with medical consumerism? In Consuming health: The commodification of health care, ed. S. Henderson and A. Petersen, 13-30. London: Routledge.
17. Frueh, F. W., and D. Gurwitz. 2004. From pharmacogenetics to personalized medicine: A vital need for educating health professionals and the community. Pharmacogenomics 5(5): 571-579.
18. Ginsburg, G. S., and J. J. McCarthy. 2001. Personalized medicine: Revolutionizing drug discovery and patient care. Trends in Biotechnology 19(12): 491-496.
19. Ginsburg, G. S., and H. F. Willard. 2009. Genomic and personalized medicine: Foundations and applications. Translational Research 154(6): 277-287.
20. Grace, V. M. 1991. The marketing of empowerment and the construction of the health consumer: A critique of health promotion. International Journal of Health Services 21(2): 329-343.
21. Grace, V. M. 1994. What is a health consumer? In Just health: Inequality in illness, care and prevention, ed. C. Waddell and A. R. Petersen, 271-283. Melbourne: Churchill Livingston.
22. Guttmacher, A. E., M. E. Porteous, and J. D. McInerney. 2007. Educating health-care professionals about genetics and genomics. Nature Reviews Genetics 8(2): 151-157.
23. Hallgrímsson, B., and B. K. Hall. 2011. Epigenetics: Linking genotype and phenotype in development and evolution. Berkeley: University of California Press.
24. Hamburg, M. A., and F. S. Collins. 2010. The path to personalized medicine. The New England Journal of Medicine 363(4): 301-304.
25. Hedgecoe, A. 2004. The politics of personalised medicine: Pharmacogenetics in the clinic. New York: Cambridge University Press.
26. Hendersen, S., and A. Petersen. 2002. Consuming health: The commodification of health care. London: Routledge.
27. Hogg, C. 1999. Patients, power and politics: From patients to citizens. London: Sage.
28. Katsios, C., and D. H. Roukos. 2010. Individual genomes and personalized medicine: Life diversity and complexity. Personalized Medicine 7(4): 347-350.
29. Khoury, M. J. 1996. From genes to public health: The applications of genetic technology in disease prevention. Genetics Working Group. American Journal of Public Health 86(12): 1717-1722.
30. Khoury, M. J. 2010. Dealing with the evidence dilemma in genomics and personalized medicine. Clinical Pharmacology and Therapeutics 87(6): 635-638.
31. Law, J. 2006. Big Pharma: How the world's biggest drug companies control illness. London: Constable and Robinson Ltd.
32. Leiss, W. 1976. The limits to satisfaction: An essay on the problem of needs and commodities. Toronto: University of Toronto Press.
33. Lunshof, J. E. 2006. Personalized medicine: New perspectives-new ethics? Personalized Medicine 3(2): 187-194.
34. Lupton, D. 1994. Consumerism, commodity culture and health promotion. Health Promotion International 9(2): 111-118.
35. Meyer, J. M., and G. S. Ginsburg. 2002. The path to personalized medicine. Current Opinion in Chemical Biology 6(4): 434-438.
36. Miringoff, M. L. 1991. The social costs of genetic welfare. New Brunswick: Rutgers University Press.
37. Moynihan, R., and A. Cassels. 2005. Selling sickness: How drug companies are turning us all into patients. Crows Nest: Allen and Unwin.
38. NHMRC. 2011. Personalised medicine and genetics. National Health and Medical Research Council, July 4. http://www. nhmrc. gov. au/your-health/egenetics/personalised-medicine. Accessed December 21, 2011.
39. Ormond, K. E., M. T. Wheeler, L. Hudgins, et al. 2010. Challenges in the clinical application of whole-genome sequencing. Lancet 375(9727): 1749-1751.
40. Petersen, A. 2006. The genetic conception of health: Is it as radical as claimed? Health 10(4): 481-500.
41. Petersen, A. 2009. The ethics of expectations: Biobanks and the promise of personalised medicine. Monash Bioethics Review 28(1): 5. 1-5. 12.
42. Petersen, A., and R. Bunton. 2002. The new genetics and the public's health. London: Routledge.
43. Petersen, A., and D. Lupton. 1996. The new public health: Health and self in the age of risk. St. Leonards: Allen and Unwin.
44. Phillips, K. A., D. L. Veenstra, S. D. Ramsey, S. L. van Bebber, and J. Sakowski. 2004. Genetic testing and pharmacogenomics: Issues for determining the impact to healthcare delivery and costs. The American Journal of Managed Care 10(7): 425-432.
45. Reardon, J. 2011. The "persons" and "genomics" of personal genomics. Personalized Medicine 8(1): 95-107.
46. Rose, N., and P. Miller. 1992. Political power beyond the state: Problematics of government. The British Journal of Sociology 43(2): 173-205.
47. Rychetnik, L., P. Hawe, E. Waters, A. Barratt, and M. Frommer. 2004. A glossary for evidence-based public health. Journal of Epidemiology and Community Health 58(7): 538-545.
48. Seshadri, R., F. A. Firgaira, D. J. Horsfall, K. McCaul, V. Setlur, and P. Kitchen. 1993. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. Journal of Clinical Oncology 11(10): 1936-1942.
49. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785): 177-182.
50. Slamon, D. J., W. Godolphin, L. A. Jones, et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905): 707-712.
51. Slamon, D. J., B. Leyland-Jones, S. Shak, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine 344(11): 783-792.
52. Smart, A., P. Martin, and M. Parker. 2004. Tailored medicine: Whom will it fit? The ethics of patient and disease stratification. Bioethics 18(4): 322-343.
53. Snyderman, R., and R. Sanders Williams. 2003. Prospective medicine: The next health care transformation. Academic Medicine 78(11): 1079-1084.
54. Taylor, S., S. Treloar, K. Barlow-Stewart, M. Stranger, and M. Otlowski. 2008. Investigating genetic discrimination in Australia: A large-scale survey of clinical genetics clients. Clinical Genetics 74(1): 20-30.
55. Thrall, J. H. 2004. Personalized medicine. Radiology 231(3): 613-616.
56. Tiles, M. 1993. The normal and pathological: The concept of a scientific medicine. The British Journal for the Philosophy of Science 44(4): 729-742.
57. Willard, H. F., M. Angrist, and G. S. Ginsburg. 2005. Genomic medicine: Genetic variation and its impact on the future of health care. Philosophical Transactions of the Royal Society B: Biological Sciences 360(1460): 1543-1550.